Oncocyte Says Study Confirms Accuracy of Lung Cancer Blood Test

OncoCyte plans a commercial launch of the test as early as the second half of this year.

- 

ONCOCYTE CORP, which is developing diagnostics in the fledgling field of liquid biopsies, said a 300-patient validation study of its blood test for early detection of lung cancer has confirmed the accuracy reported from a prior trial.

OncoCyte said it was preparing for a commercial launch of the test as early as the second half of this year and expects it will be the first product of its kind for lung cancer to reach the market.

Liquid biopsies use blood or urine to determine the presence of cancer and can help spare patients from unnecessary invasive biopsies, that are risky, expensive and most often find tested tissue to be benign.